Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, would cost patients between ₹14,000 to ₹17,500 monthly.

US pharma major Eli Lilly has launched in India its eagerly awaited diabetes and obesity drug Mounjaro tripeptide Read ahead to know more!

The new class of weight-loss medicines that has taken the world by a storm will now become available in India, with the pharmaceutical giant Eli Lilly on Thursday announcing the launch of tirzepatide to be marketed as Mounjaro. The medicine will be available in a single-dose vial, meant to be taken as a shot under the skin every week.

US giant, Eli Lilly launched Mounjaro (tirzepatide) which is a prescription medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose).

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what you need to know

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and Ozempic, another popular obesity drug, differ in active ingredients. Let’s take a look at how both drugs tackle type 2 diabetes.